Books

A New Model For Health And Disease – Page 129

The idea that the FDA (U.S. Food and Drug Administration) exerts some control over the distribution of products to the American market and works for the best interests of the public is, in my opinion, misleading, because the people in the administration are usually of the same mind as the researchers. They do not adhere to or apply different principles in viewing the efficacy and danger of the drugs. So, although their intervention prevents to some extent extremely dangerous drugs from flood¬ing the market with devastating results, the FDA does not solve the whole problem.
Silverman and Lee quote various disastrous examples of pharmaceutical promotion, such as the sulfanilamide affair in 1938, the chloramphenicol affair in the 1950s, the MER/29 (triparanol) affair in 1959, the affair of oral contraceptives, and the case of oral anti-diabetic agents.6
"The welter of documents available in the offices of the SEC confirm the conclusion from interviews with industry executives: bribery is routine and widespread in the international pharmaceutical industry and large amounts of money are involved. Almost every type of person who can affect the interests of the industry has been the subject of bribes by pharmaceutical companies: doctors, hospital administrators, cabinet ministers, health inspectors, customs officers, tax assessors, drug registration officials, factory inspectors, pricing officials, and political parties.
"….The problem of suppression of facts is widespread. A typical case occurs along the following lines: a toxicological study has been conducted and gives an equivocal result or a result unfavorable to the product. A second study is conducted and at times even a third in which the dose levels are adjusted or the protocols modified in such a way that eventually a result favorable to the applicant’s product is obtained. Only the result favorable to the applicant’s product is submitted to the regulatory authority….Microscopic examinations of histopathological slides may be made by more than one pathologist each of whom may have come to different conclusions, yet only the conclusions favorable to the drug are submitted to the regulatory authority. On one occasion where such a situation has been detected the applicant with a dismissive gesture said ‘that investigator gives the wrong results; we will not use him again.’ (This attitude reveals the commercial pressure that can be brought to bear on an investigator by the threat of loss of future work.)"7
33. Signs and symptoms are not the disease per se, but an expression of the unique way in which the individual’s defense system is trying to eradicate the disease.